Article

No evidence for WT1 involvement in a beta-catenin-independent activation of the Wnt signaling pathway in pituitary adenomas.

Institute of Brain Research, University of Tübingen, Calwerstr. 3, 72076, Tübingen, Germany.
Endocrine Pathology (impact factor: 1.36). 06/2009; 20(3):158-62. DOI:10.1007/s12022-009-9078-y pp.158-62
Source: PubMed

ABSTRACT The overexpression of Wilms' tumor gene product WT1, which acts as a tumor suppressor or oncogene, has been reported in various malignancies. Recent studies have shown that the interaction partner Wnt-4 is upregulated in pituitary adenomas dependent on the Pit-1 lineage (somatotrophs, lactotrophs, and thyrotrophs). However, no data on WT1 expression in nontumorous pituitary tissue or pituitary adenomas is available to date. We investigated WT1 expression in 90 paraffin-embedded pituitary adenomas, including eight atypical adenomas, and in 28 nontumorous pituitary glands by immunohistochemistry. WT1 is absent in epithelial cells of all nontumorous pituitary glands and in 87 out of 90 pituitary adenomas. Only two GHomas (including one atypical adenoma) and one gonadotropin-producing adenoma expressed WT1 in the cytoplasm of single tumor cells without nuclear staining. There is no evidence that WT1 does regulate the Wnt-4/beta-catenin-independent pathway which is activated in the Pit-1-expressing subset of pituitary adenomas.

0 0
 · 
0 Bookmarks
 · 
22 Views

Keywords

28 nontumorous pituitary glands
 
90 paraffin-embedded pituitary adenomas
 
90 pituitary adenomas
 
atypical adenoma
 
atypical adenomas
 
cytoplasm
 
immunohistochemistry
 
interaction partner Wnt-4
 
nontumorous pituitary glands
 
nontumorous pituitary tissue
 
nuclear staining
 
Pit-1-expressing subset
 
pituitary adenomas
 
pituitary adenomas dependent
 
Recent studies
 
single tumor cells
 
tumor suppressor
 
various malignancies
 
Wilms' tumor gene product WT1
 
WT1 expression